Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating abciximab, an anti-platelet therapy, in patients with unstable angina undergoing coronary angioplasty have completed, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unstable Angina

Drugs mentioned

• Abciximab (abciximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary | Phase 3 | Status: COMPLETED